Dual vs Single Immune Checkpoint Inhibitors in BRAF V600–Negative Advanced Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Improved overall survival in dual compared to single immune checkpoint inhibitors in BRAF V600-negative advanced melanoma
Melanoma Manag 2022 Apr 26;9(1)MMT60, A Kartolo, C Yeung, M Kuksis, W Hopman, T BaetzFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.